GLP-1s, Urolithin A & Urolithin B: Uncovering the Mitochondria-Metabolism-Brain Axis episode artwork

EPISODE · Aug 20, 2026 · 45 MIN

GLP-1s, Urolithin A & Urolithin B: Uncovering the Mitochondria-Metabolism-Brain Axis

from The Energy Code · host Dr. Mike Belkowski

Could metabolic aging, chronic anxiety, and depression all share the same biological root? In this episode of The Energy Code, Dr. Mike Belkowski reviews three newly published studies that, when viewed together, point toward an emerging concept he calls the mitochondria-metabolism-brain axis. The first paper explores how GLP-1 medications may influence mitochondrial biology beyond weight loss by interacting with pathways involved in mitochondrial biogenesis, oxidative stress, and cellular resilience. The second investigates how Urolithin A restored mitophagy and eliminated anxiety-like behavior in animal models. The third demonstrates how Urolithin B improved depression-like behavior by activating mitochondrial quality-control pathways through SLP2 and the PINK1/Parkin signaling system. While much of the evidence remains preclinical, the convergence across these independent research groups is striking. Rather than focusing on three different diseases, the episode explores one shared biological thread: mitochondrial quality control. If these findings continue to translate into humans, they could fundamentally reshape how we think about metabolism, aging, inflammation, resilience, and brain health. (Educational content only, not medical advice.) - Articles Discussed in Episode: The GLP-1–Mitochondria Axis in Metabolic Aging Urolithin A Abolishes High Anxiety and Rescues the Associated Mitochondria-Related Transcriptomic Signatures and Synaptic Function Urolithin B Ameliorates Depressive-Like Behavior and Hippocampal Neuronal Damage in Depressed Rats via Regulation of the SLP2/PINK1/Parkin Signaling Pathway - Key Quotes From Dr. Mike: "The real question isn't whether one of these compounds works — it's whether we're uncovering a broader mitochondria-metabolism-brain axis." "Mitochondrial dysfunction sits at the center of metabolic aging." "GLP-1 drugs may be touching the exact mitochondrial machinery that declines with age." "Urolithin A didn't simply reduce anxiety — it appeared to restore the mitochondrial quality control system underlying it." "Urolithin B improved behavior, protected hippocampal neurons, and reduced neuroinflammation." "Mitochondrial quality control may be one of the shared nodes connecting metabolism, aging, inflammation, and the brain." "The mitochondrion is beginning to look less like a power plant and more like a resilience hub." - Key Points ⚡ Three newly published studies explored metabolic aging, anxiety, and depression—but all converged on mitochondrial biology as a shared mechanism. ⚡ The episode introduces the emerging concept of the mitochondria-metabolism-brain axis. ⚡ A new Aging Cell review proposes that mitochondrial dysfunction sits at the center of metabolic aging. ⚡ Age-related declines in NAD, sirtuins, PGC-1α, mitochondrial biogenesis, and mitophagy may collectively drive metabolic decline. ⚡ GLP-1 receptor agonists may influence mitochondrial function through AMPK, PGC-1α, NRF2, and mitophagy pathways. ⚡ Despite compelling mechanisms, direct mitochondrial benefits of GLP-1 drugs in humans remain an active hypothesis—not established fact. ⚡ Large clinical trials continue to demonstrate significant cardiovascular and metabolic benefits from GLP-1 therapies. ⚡ Neurons have extraordinarily high energy demands, making the brain especially vulnerable to mitochondrial dysfunction. ⚡ A new Biological Psychiatry study found that Urolithin A eliminated anxiety-like behavior in multiple rodent models. ⚡ Urolithin A restored mitochondrial quality control by improving mitophagy through the PINK1/Parkin pathway. ⚡ The anti-anxiety effects occurred without sedation and primarily benefited animals exhibiting high anxiety. ⚡ Urolithin A also restored neuronal connectivity, dendritic complexity, synaptic function, and Mitofusin-2 expression. ⚡ A second study found that Urolithin B significantly improved depression-like behavior in stressed rats. ⚡ Urolithin B reduced neuroinflammation, preserved hippocampal neurons, increased BDNF and serotonin, and lowered corticosterone. ⚡ Researchers identified SLP2 as a key upstream regulator driving PINK1/Parkin-mediated mitophagy. ⚡ Knocking down SLP2 largely eliminated Urolithin B's protective effects, strengthening the proposed mechanism. ⚡ All three papers independently converged on mitochondrial quality control and mitophagy as central biological processes. ⚡ The PINK1/Parkin pathway appeared repeatedly across metabolic aging, anxiety, and depression research. ⚡ Mitochondrial quality control may represent a shared biological node linking seemingly unrelated chronic diseases. ⚡ The most important takeaway isn't any single molecule—it's the growing evidence that mitochondrial resilience may influence multiple organ systems simultaneously. - Episode timeline 00:00 – One Question Connects Three Diseases Could metabolic aging, anxiety, and depression all share one biological mechanism? 02:30 – The GLP-1 Mitochondrial Axis Aging Cell review Mitochondrial dysfunction and metabolic aging NAD, sirtuins, PGC-1α, mitophagy Human vs. animal evidence 16:40 – Why the Brain Depends on Healthy Mitochondria Neuronal energy demands Why mitochondrial dysfunction disproportionately affects the brain 18:40 – Urolithin A and Anxiety Biological Psychiatry study Anxiety models Mitophagy restoration PINK1/Parkin pathway Mitofusin-2 27:00 – Urolithin B and Depression Brain Research Bulletin study SLP2 signaling PINK1/Parkin activation Hippocampal neuroprotection Behavioral improvements 36:30 – The Bigger Picture How all three studies converge The mitochondria-metabolism-brain axis Why mitochondrial quality control may become one of the defining concepts in longevity science 41:30 – Final Takeaways What we know What remains speculative Why this emerging field deserves close attention - Dr. Mike's #1 recommendations: Deuterium depleted water: Litewater (code: DRMIKE) EMF-mitigating products: Somavedic (code: BIOLIGHT) Blue light blocking glasses: Ra Optics (code: BIOLIGHT) Grounding products: Earthing.com - Stay up-to-date on social media: Dr. Mike Belkowski: Instagram LinkedIn   BioLight Labs:  Website Instagram   BioLight: Website Instagram YouTube Facebook

Episode metadata supplied by the publisher feed · Published Aug 20, 2026

Embed this episode

Could metabolic aging, chronic anxiety, and depression all share the same biological root? In this episode of The Energy Code, Dr. Mike Belkowski reviews three newly published studies that, when viewed together, point toward an emerging concept he calls the mitochondria-metabolism-brain axis. The first paper explores how GLP-1 medications may influence mitochondrial biology beyond weight loss by interacting with pathways involved in mitochondrial biogenesis, oxidative stress, and cellular resilience. The second investigates how Urolithin A restored mitophagy and eliminated anxiety-like behavior in animal models. The third demonstrates how Urolithin B improved depression-like behavior by activating mitochondrial quality-control pathways through SLP2 and the PINK1/Parkin signaling system. While much of the evidence remains preclinical, the convergence across these independent research groups is striking. Rather than focusing on three different diseases, the episode explores one shared biological thread: mitochondrial quality control. If these findings continue to translate into humans, they could fundamentally reshape how we think about metabolism, aging, inflammation, resilience, and brain health. (Educational content only, not medical advice.) - Articles Discussed in Episode: The GLP-1–Mitochondria Axis in Metabolic Aging Urolithin A Abolishes High Anxiety and Rescues the Associated Mitochondria-Related Transcriptomic Signatures and Synaptic Function Urolithin B Ameliorates Depressive-Like Behavior and Hippocampal Neuronal Damage in Depressed Rats via Regulation of the SLP2/PINK1/Parkin Signaling Pathway - Key Quotes From Dr. Mike: "The real question isn't whether one of these compounds works — it's whether we're uncovering a broader mitochondria-metabolism-brain axis." "Mitochondrial dysfunction sits at the center of metabolic aging." "GLP-1 drugs may be touching the exact mitochondrial machinery that declines with age." "Urolithin A didn't simply reduce anxiety — it appeared to restore the mitochondrial quality control system underlying it." "Urolithin B improved behavior, protected hippocampal neurons, and reduced neuroinflammation." "Mitochondrial quality control may be one of the shared nodes connecting metabolism, aging, inflammation, and the brain." "The mitochondrion is beginning to look less like a power plant and more like a resilience hub." - Key Points ⚡ Three newly published studies explored metabolic aging, anxiety, and depression—but all converged on mitochondrial biology as a shared mechanism. ⚡ The episode introduces the emerging concept of the mitochondria-metabolism-brain axis. ⚡ A new Aging Cell review proposes that mitochondrial dysfunction sits at the center of metabolic aging. ⚡ Age-related declines in NAD, sirtuins, PGC-1α, mitochondrial biogenesis, and mitophagy may collectively drive metabolic decline. ⚡ GLP-1 receptor agonists may influence mitochondrial function through AMPK, PGC-1α, NRF2, and mitophagy pathways. ⚡ Despite compelling mechanisms, direct mitochondrial benefits of GLP-1 drugs in humans remain an active hypothesis—not established fact. ⚡ Large clinical trials continue to demonstrate significant cardiovascular and metabolic benefits from GLP-1 therapies. ⚡ Neurons have extraordinarily high energy demands, making the brain especially vulnerable to mitochondrial dysfunction. ⚡ A new Biological Psychiatry study found that Urolithin A eliminated anxiety-like behavior in multiple rodent models. ⚡ Urolithin A restored mitochondrial quality control by improving mitophagy through the PINK1/Parkin pathway. ⚡ The anti-anxiety effects occurred without sedation and primarily benefited animals exhibiting high anxiety. ⚡ Urolithin A also restored neuronal connectivity, dendritic complexity, synaptic function, and Mitofusin-2 expression. ⚡ A second study found that Urolithin B significantly improved depression-like behavior in stressed rats. ⚡ Urolithin B reduced neuroinflammation, preserve

Distinct summary based on available episode metadata or transcript content.

Ready to play

GLP-1s, Urolithin A & Urolithin B: Uncovering the Mitochondria-Metabolism-Brain Axis

0:00 45:40

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Energy Code?

This episode is 45 minutes long.

When was this The Energy Code episode published?

This episode was published on August 20, 2026.

Can I download this The Energy Code episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!